Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
25600 participants
OBSERVATIONAL
2021-07-26
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The aim of this study is to identify psychophysiological and biological risk factors for the development of chronic abdominal pain in patients with newly diagnosed IBD (ulcerative colitis and Crohn's disease).
This study consists of 4 sections (Study 1A, 1B, 2, and 3):
Study 1A: We perform a longitudinal study in 150 patients with new-onset IBD over 18 months to identify risk factors related to the brain-gut axis for the development of chronic pain. This is a collaborative study with IBD BioResourse Inception study. We administer online questionnaires, collect stool and blood samples, and record heart rate. Other physiological data collected by the Inception study will be also used for the analysis.
Study 1B: This is also a collaborative study with the Inception study. We will apply for our detailed questionnaires for 7 days (as per study 1A) to be administered to all the new patients (n=450) that are included in the Inception study on a voluntary basis. Patients will be followed for 12 months.
Study 2 and 3: Study 2 and 3 are a questionnaire-based cross-sectional study in patients with IBD. The participants for study 2 are patients registered in IBD BOOST study and those for study 3 are patients registered in IBD BioResource (but not in IBD Boost study). Detailed online questionnaires will be administered to them. These studies are just one-day assessment.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Multi-factor Analysis of Psychological Disorders in IBD Patients
NCT04939948
The Influence of Information Sources on Knowledge and Anxiety in Inflammatory Bowel Disease Patients
NCT01916161
Study of the Psychometric Properties of Two Questionnaires for Measuring Disease Flare-up in IBD
NCT06214299
A Multidisciplinary Approach to Assessing and Treating Fatigue in Inflammatory Bowel Disease
NCT05906043
Impact of Obesity on Response to Therapy and Clinical Outcom in Patients With Inflammatory Bowel Disease
NCT07343726
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Study 1A: We perform a longitudinal study in 150 patients with new-onset IBD (UC and CD) over 18 months to identify risk factors related to the brain-gut axis for the development of chronic pain.
First assessment period: On the first day of the study, we will have a video chat with the participant using one of the telecommunications applications (e.g. skype, zoom, Microsoft team, etc.) and obtain an electric consent form using DocuSign (https://www.docusign.co.uk/). Then, participants will be trained on how to use online validated questionnaires to evaluate their disease activity, symptoms and psychological state, presence or absence of irritable bowel syndrome (IBS), or pain elsewhere. Then, they will be asked to download a mobile phone camera heart rate variability app and be trained to use it. They will also be trained to use the experience sampling method (ESM) to profile gut symptoms and lifestyle via a smartphone app at 10 random times in a day.
After training, participants will fill out baseline online questionnaires using REDCap. Participants will also start answering questionnaires by ESM for 7 days and recording their heart rate (5 minutes) using the app once a day in the morning for 7 days.
2nd-4th assessment periods: Further assessment periods will be scheduled every 6 months. One-two days before each study period begins, we will remind the participants by email or phone call. On day 1, participants fill out the same online questionnaires (except personality, which is a stable trait) followed by 7 days ESM profiling as during their first assessment period. They will also be asked to record heart rate (5 minutes) once a day in the morning for 7days. Each patient will be followed at least 18 months until the 4th assessment period ends.
If patients agree, we will add online questionnaires to patients beyond the life of the grant (at 24 months and 36 months) when they are followed by the IBD BioResource inception study. (ESM and sample collection are not performed after 18 months follow)
This is a collaborative study with the IBD BioResource Inception study. The participants in our study will be asked to participate in the IBD BioResource Inception study as well. Biological data obtained by the BioResource Inception study, which will be used for the analysis.
Study 1B: This is also a collaborative study with the Inception study. Data for 600 patients will still need to be collected by the Inception study when our study starts. We will apply for our detailed questionnaires for 7 days (as per study 1A) to be administered to all the new patients that are included in the Inception study on a voluntary basis. This will allow us to capture data on almost 600 patients (150 of these will be from study 1A).
Using both our 150 studied patients from study1A and 450 patients in the Inception cohort (study 1B), we will then use cutting edge techniques in machine learning to ascertain if artificial intelligence (AI) can predict individuals who will develop chronic abdominal pain.
Study 2 and 3: Study 2 and 3 are a questionnaire-based cross-sectional study in patients with IBD (both CD and UC patients). The participants for study 2 are patients who are registered in IBD BOOST study and those for study 3 are patients who are registered in IBD BioResource (but not in IBD Boost study).
The aims are to determine the prevalence of chronic pain in Crohn's and UC patients, the prevalence of comorbid pain and IBS, lifestyle factors, and quality of life. IBD BOOST questionnaire is due to be administered to 10,000 patients. We will invite these patients to complete additional questionnaires not covered by IBD BOOST. We also approach 15,000 patients from IBD BioResourse who are not included in the IBD Boost study and administer questionnaires to them. We will be able to identify risk factors and aid a predictive model from static time point data if a number of those individuals have pain and a number do not. Further, in study 2 and 3, we will be able to determine whether the risk factors identified in study 1A and 1B accurately identify patients with and without chronic pain.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Study 1A
Prospective cohort study with 150 newly diagnosed patients with inflammatory bowel disease
Assessment of Psychophysiological factors
Investigating the presence of psychophysiological factors (depression, anxiety, catastrophizing) by questionnaires.
Assessment of Biological factors
Investigating autonomic nervous function using heart rate recording, colon biopsy samples, microbiota, and blood cytokines levels. (Colon biopsy samples are obtained when colonoscopy is performed for clinical reasons. Blood samples and stool samples will be taken when participants come to the hospital for colonoscopy)
Assessment of Genetics
Genetic data investigated by another cohort study (IBD BioResource study) will be utilized in the analysis of this study.
Assessment of Quality of Life
Investigating QOL by questionnaires.
Study 1B
Prospective cohort study with 450 newly diagnosed patients with IBD
Assessment of Psychophysiological factors
Investigating the presence of psychophysiological factors (depression, anxiety, catastrophizing) by questionnaires.
Assessment of Genetics
Genetic data investigated by another cohort study (IBD BioResource study) will be utilized in the analysis of this study.
Assessment of Quality of Life
Investigating QOL by questionnaires.
Assessment of Biological factors
Investigating colon biopsy samples (Colon biopsy samples are obtained when colonoscopy is performed for clinical reasons).
Study 2
Cross-sectional study with 10,000 patients in IBD Boost study
Assessment of Psychophysiological factors
Investigating the presence of psychophysiological factors (depression, anxiety, catastrophizing) by questionnaires.
Assessment of Genetics
Genetic data investigated by another cohort study (IBD BioResource study) will be utilized in the analysis of this study.
Assessment of Quality of Life
Investigating QOL by questionnaires.
Study 3
Cross-sectional study with 15,000 patients in IBD BioResource
Assessment of Psychophysiological factors
Investigating the presence of psychophysiological factors (depression, anxiety, catastrophizing) by questionnaires.
Assessment of Genetics
Genetic data investigated by another cohort study (IBD BioResource study) will be utilized in the analysis of this study.
Assessment of Quality of Life
Investigating QOL by questionnaires.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Assessment of Psychophysiological factors
Investigating the presence of psychophysiological factors (depression, anxiety, catastrophizing) by questionnaires.
Assessment of Biological factors
Investigating autonomic nervous function using heart rate recording, colon biopsy samples, microbiota, and blood cytokines levels. (Colon biopsy samples are obtained when colonoscopy is performed for clinical reasons. Blood samples and stool samples will be taken when participants come to the hospital for colonoscopy)
Assessment of Genetics
Genetic data investigated by another cohort study (IBD BioResource study) will be utilized in the analysis of this study.
Assessment of Quality of Life
Investigating QOL by questionnaires.
Assessment of Biological factors
Investigating colon biopsy samples (Colon biopsy samples are obtained when colonoscopy is performed for clinical reasons).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients who are diagnosed with UC or CD within 6 months before the enrolment.
* Patients who have access to the internet and have the IT skills to perform basic tasks e.g. operate emails and fill out questionnaires.
* Patients who are willing and able to participate in the study for the required duration, can understand and are willing to sign the consent forms and agree to undergo all protocol-related tests and procedures.
Exclusion Criteria
* Patients who already have the presence of a stoma or history of a fistula or stricture due to another diagnosis.
* Patients who are pregnant, lactating or thinking of becoming pregnant during the study period
* Patients who have unstable acute illness or exacerbation of an unstable chronic illness or chronic disease (other than IBD) that may affect assessments for this study as determined by previous physical examination, medical history, vital signs, ECG, and laboratory (serum biochemistry, hematology, urinalysis) assessments.
* Patients with a medical history of hepatitis B, hepatitis C or human immunodeficiency virus (HIV) infection that are not in remission and are on medication that can affect gastrointestinal function.
* Patients who have known or suspected to have a severe cardiac disease (e.g., symptomatic coronary artery disease, prior myocardial infarction, congestive heart failure (CHF) and chronic arrhythmia such as atrial fibrillation
* Patients who have known or suspected cerebrovascular disease (e.g. prior stroke or transient ischemic attack, symptomatic carotid artery disease, prior carotid endarterectomy or other vascular neck surgery)
* Patients who have a known history or suspected history of substance abuse or addiction (within the last five years).
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Birmingham
OTHER
University of Cambridge
OTHER
Barking, Havering and Redbridge University Hospitals NHS Trust
OTHER
Barts & The London NHS Trust
OTHER
University College London Hospitals
OTHER
Royal Free Hospital NHS Foundation Trust
OTHER
King's College London
OTHER
Queen Mary University of London
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Qasim Aziz
Role: PRINCIPAL_INVESTIGATOR
Wingate Institute of Neurogastroenterology, Barts and the London School of Medicine and Dentistry, Queen Mary University of London
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Neurogastroenterology, Barts and the London School of Medicine and Dentistry, Queen Mary University of London
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
279414
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.